Modality
siRNA
MOA
CD3xCD20
Target
PD-L1
Pathway
DDR
LN
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
~Sep 2020
→ ~Dec 2021
Phase 2
~Mar 2022
→ ~Jun 2023
Phase 3
~Sep 2023
→ ~Dec 2024
NDA/BLA
Mar 2025
→ Oct 2026
NDA/BLACurrent
NCT03573368
94 pts·LN
2025-03→2026-10·Completed
94 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-257mo awayPh3 Readout· LN
Trial Timeline
Q2Q3Q42026Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-10-25 · 7mo away
LN
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03573368 | NDA/BLA | LN | Completed | 94 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Polatuximab | Nuvalent | Approved | PD-L1 |